Tags

Type your tag names separated by a space and hit enter

Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension.
Biorheology. 2016 01 27; 53(1):13-22.B

Abstract

OBJECTIVES

Drag-reducing polymers (DRPs) are blood-soluble macromolecules which may increase blood flow and reduce vascular resistance. The purpose of the present study was to observe the effect of DRPs on monocrotaline-induced pulmonary hypertension (PH) in the rat model.

METHODS

A total of 64 male Wistar rats were randomly divided into four groups: Group I (pulmonary hypertension model + DRP treatment); Group II (pulmonary hypertension model + saline treatment); Group III (control + DRP treatment); Group IV (control + saline treatment). After five weeks, comparisons were made of the following indices: survival rate, body weight, blood pressure, right ventricular systolic pressure, right ventricular hypertrophy, wall thickness of pulmonary arteries, the internal diameter of small pulmonary arteries, plasma IL-1β and IL-6.

RESULTS

The survival rate after 5 weeks varied significantly across all groups (P=0.013), but the survival rates of Groups I and II were not statistically significantly different. Administration of DRP (intravenous injection twice weekly) attenuated the PH-induced increase in right ventricular systolic pressure and suppressed the increases in right ventricular (RV) weight and the ratio of right ventricular weight to left ventricle plus septum weight (RV/LV + S). DRP treatment also significantly decreased the wall thickness of pulmonary arteries, augmented the internal diameter of small pulmonary arteries, and suppressed increases in the plasma levels of IL-1β and IL-6.

CONCLUSIONS

DRP treatment with intravenous injection effectively inhibited the development of monocrotaline-induced pulmonary hypertension in the rat model. DRPs may have potential application for the treatment of pulmonary hypertension.

Authors+Show Affiliations

Department of Respiratory Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.Department of Cardiovascular Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.Department of Respiratory Diseases, Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Respiratory Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.Department of Respiratory Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.Department of Cardiovascular Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.Department of Cardiovascular Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.Department of Cardiovascular Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.Department of Cardiovascular Diseases, The Second Clinical Medical College, Yangzhou University, Yangzhou, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26889655

Citation

Wang, Yali, et al. "Protective Effects of Drag-reducing Polymers in a Rat Model of Monocrotaline-induced Pulmonary Hypertension." Biorheology, vol. 53, no. 1, 2016, pp. 13-22.
Wang Y, Hu F, Mu X, et al. Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension. Biorheology. 2016;53(1):13-22.
Wang, Y., Hu, F., Mu, X., Wu, F., Yang, D., Zheng, G., Sun, X., Gong, K., & Zhang, Z. (2016). Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension. Biorheology, 53(1), 13-22. https://doi.org/10.3233/BIR-15062
Wang Y, et al. Protective Effects of Drag-reducing Polymers in a Rat Model of Monocrotaline-induced Pulmonary Hypertension. Biorheology. 2016 01 27;53(1):13-22. PubMed PMID: 26889655.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension. AU - Wang,Yali, AU - Hu,Feng, AU - Mu,Xiaoyan, AU - Wu,Feng, AU - Yang,Dechun, AU - Zheng,Guixiang, AU - Sun,Xiaoning, AU - Gong,Kaizheng, AU - Zhang,Zhengang, PY - 2016/2/19/entrez PY - 2016/2/19/pubmed PY - 2017/5/10/medline KW - Drag-reducing polymers KW - monocrotaline KW - pulmonary hypertension SP - 13 EP - 22 JF - Biorheology JO - Biorheology VL - 53 IS - 1 N2 - OBJECTIVES: Drag-reducing polymers (DRPs) are blood-soluble macromolecules which may increase blood flow and reduce vascular resistance. The purpose of the present study was to observe the effect of DRPs on monocrotaline-induced pulmonary hypertension (PH) in the rat model. METHODS: A total of 64 male Wistar rats were randomly divided into four groups: Group I (pulmonary hypertension model + DRP treatment); Group II (pulmonary hypertension model + saline treatment); Group III (control + DRP treatment); Group IV (control + saline treatment). After five weeks, comparisons were made of the following indices: survival rate, body weight, blood pressure, right ventricular systolic pressure, right ventricular hypertrophy, wall thickness of pulmonary arteries, the internal diameter of small pulmonary arteries, plasma IL-1β and IL-6. RESULTS: The survival rate after 5 weeks varied significantly across all groups (P=0.013), but the survival rates of Groups I and II were not statistically significantly different. Administration of DRP (intravenous injection twice weekly) attenuated the PH-induced increase in right ventricular systolic pressure and suppressed the increases in right ventricular (RV) weight and the ratio of right ventricular weight to left ventricle plus septum weight (RV/LV + S). DRP treatment also significantly decreased the wall thickness of pulmonary arteries, augmented the internal diameter of small pulmonary arteries, and suppressed increases in the plasma levels of IL-1β and IL-6. CONCLUSIONS: DRP treatment with intravenous injection effectively inhibited the development of monocrotaline-induced pulmonary hypertension in the rat model. DRPs may have potential application for the treatment of pulmonary hypertension. SN - 1878-5034 UR - https://www.unboundmedicine.com/medline/citation/26889655/Protective_effects_of_drag_reducing_polymers_in_a_rat_model_of_monocrotaline_induced_pulmonary_hypertension_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/BIR-15062 DB - PRIME DP - Unbound Medicine ER -